The FDA has cleared daraxonrasib, the first RAS(ON) tri-complex inhibitor to reach approval, validating a mechanism-driven platform approach to a historically undruggable oncogene family in pancreatic cancer.
The FDA has approved daraxonrasib (Rasonque) for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy, the first regulatory clearance for a RAS(ON)-class inhibitor and a validation of the tri-complex mechanism that Revolution Medicines has pursued since 2014.1
“The FDA approval of Rasonque is a monumental step forward for patients with pancreatic cancer and for the oncology field. For the first time, patients have an approved targeted medicine designed to directly inhibit the main cause of pancreatic cancer, RAS, which has been one of the most intractable disease targets since its discovery decades ago,” said Mark A. Goldsmith, MD, PhD, chief executive officer and chairman of Revolution Medicines, in a press release. “The unprecedented results of the global Phase 3 trial position Rasonque to become the new standard of care for patients with metastatic pancreatic cancer under an approved label that supports real-world clinical decision-making. This approval further validates our bold RAS(ON) inhibitor strategy that includes multi-selective and mutant-selective approaches targeting a major driver of pancreatic cancer and multiple other cancers. We continue to engage with global regulatory authorities with the goal of expanding and accelerating the reach of Rasonque.”
The oral, once-daily small molecule was approved roughly six and a half months ahead of its user-fee action date, under a review pathway that combined four separate expedited designations.
For process development and regulatory affairs teams, the approval offers a case study in how platform-level medicinal chemistry, biomarker strategy, and a stacked designation pathway can compress a development timeline for a historically difficult target.
“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, director of the FDA’s Oncology Center of Excellence, noting that the approval timeline “demonstrat[es] the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions.”1
RAS proteins cycle between an inactive, guanosine diphosphate-bound state and an active, guanosine triphosphate-bound state; oncogenic mutations lock the protein in the active conformation, and that state has long resisted small-molecule drugging because it lacks an accessible binding pocket.
Daraxonrasib is built on a cyclophilin A-mediated tri-complex approach: the molecule binds the cyclophilin A protein first, and the resulting complex then engages active-state RAS, sterically blocking effector binding and halting downstream signaling.2
Because the mechanism targets the GTP-bound state directly rather than a single mutant allele, it engages multiple KRAS, HRAS, and NRAS variants and wild-type RAS in one molecule, a multiselective profile distinct from earlier mutation-specific inhibitors that reach only a narrow patient subset.
The open-label phase 1/2 RMC-6236-001 study established the foundational safety and dosing data, enrolling patients with advanced RAS-mutated solid tumors and testing doses from 10 to 400 mg once daily before selecting 300 mg for phase 3.3 That 168-patient pancreatic cohort reported treatment-related adverse events, most commonly rash, diarrhea, nausea, and stomatitis, in the large majority of patients, with grade 3 or higher events in roughly a third.3
Those findings supported progression to RASolute 302, a randomized, open-label, multicenter phase 3 trial in 500 patients with previously treated metastatic disease, which reported a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy.2
The application carried Breakthrough Therapy and Orphan Drug designations alongside Priority Review, and it was reviewed under the FDA's Commissioner's National Priority Voucher pilot program, intended to speed applications addressing national public health priorities.1 In May, the agency issued a “safe to proceed” letter permitting an expanded access protocol, giving patients pre-approval access under existing regulations while the review continued.1
Layering these pathways is increasingly common for oncology candidates with early, large-magnitude effect sizes, and it compresses the interval between pivotal data and commercial launch, a variable that manufacturing and supply chain teams need to plan against well before a filing decision is finalized.
As a small-molecule oral tablet rather than a biologic or conjugate, daraxonrasib's production draws on conventional synthetic chemistry and solid-dosage manufacturing rather than the cell-culture or bioconjugation infrastructure that dominates much of current oncology supply.
Patient selection depends on confirming RAS mutation status, since activating mutations occur in more than 90% of pancreatic ductal adenocarcinoma tumors and the FDA label does not limit use of Rasonque to patients with an identified RAS mutation.2 Broader adoption will likely track alongside the availability.
A companion phase 3 trial combining daraxonrasib with a second RAS(ON) molecule in first-line disease is already underway, which may eventually clarify whether combination regimens, and the biomarker and manufacturing coordination they require, extend the platform's reach beyond second-line use.
Sources
1. US Food and Drug Administration. FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer. News release. August 26, 2026.
2. O'Reilly EM, Wainberg ZA, Hendifar AE, et al; RASolute 302 Trial Investigators. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026;395(4):325-337.
3. Wolpin BM, Park W, Garrido-Laguna I, et al; RMC-6236-001 Investigators. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N Engl J Med. 2026;394(18):1790-1802.
